New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
jarmoluk / Pixabay

New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia

According to a publication from Scleroderma News, a recent study published in Rheumatology International suggests that the majority of systemic sclerosis patients experience sarcopenia as a result of their condition. Perhaps…

Continue Reading New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint
mwooten / Pixabay

The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint

According to a story from Medpage Today, a recent study testing the medication abatacept (marketed as Orencia) as a treatment for diffuse cutaneous systemic sclerosis concluded with rather mixed results.…

Continue Reading The Drug Abatacept Appears Beneficial in Systemic Sclerosis Despite Missing Primary Endpoint
A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released
mohamed_hassan / Pixabay

A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released

An open-label extension of a Phase II study has shown that the experimental drug lenabasum is fairly safe and tolerable in patients who have diffuse cutaneous systemic sclerosis. The full…

Continue Reading A Study Investigated a Possible Drug For Treating Diffuse Cutaneous Systemic Sclerosis, and the Results Have Just Been Released